Astal Laboratories to Acquire Sriven Pharmachem India for Rs. 277,16,95,017 through Share Swap

Astal Laboratories Ltd. has approved the acquisition of 100% equity shares of Sriven Pharmachem India Private Limited (SPIPL) from its existing shareholder. The acquisition will be through a share swap at a ratio of 1:1, amounting to a consideration of Rs. 277,16,95,017. SPIPL is engaged in developing and producing high profile drug intermediates and specialty chemicals, with a turnover of Rs. 1,027,009,061 for the financial year April-March 2025. The acquisition aligns with Astal Laboratories' long-term vision of becoming a fully integrated pharmaceutical manufacturing company, and is expected to contribute to improved operational strength, profitability, and shareholder value.